Vir Biotechnology, Inc. (VIR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 24.93 |
| Open | 24.90 |
| Bid | 22.16 x 1800 |
| Ask | 23.85 x 1100 |
| Day's Range | 23.26 - 25.13 |
| 52 Week Range | 18.21 - 58.00 |
| Volume | |
| Avg. Volume | 1,706,071 |
| Market Cap | 3.188B |
| Beta (5Y Monthly) | -0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.80 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.29 |
- GlobeNewswire
Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20, 2022, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast. Vir Biotechnology’s stockholders of record as of March 28, 2022 (the “Record Date”) can attend and vote at the Annual Meeting by accessing the meeting center at www.virtualshareholdermeeting.com/VIR2
- Zacks
AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.
- Benzinga
HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty
Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc (NASDAQ: VIR). The analyst maintained a Buy rating on VIR shares. The analyst continues to view Vir's platform, validated with successful antiviral therapies against Ebola and COVID-19, and pipeline, which includes compounds in development for chronic hepatitis B virus (CHB), human immunodeficiency viru
